VOLITIONRX
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease is present. As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accuratel... y, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.
VOLITIONRX
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2010-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.volition.com
Total Employee:
11+
Status:
Active
Contact:
202-618-1750
Email Addresses:
[email protected]
Total Funding:
35.63 M USD
Technology used in webpage:
SPF Google Tag Manager Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Sectigo SSL Sectigo Domain SSL Pound Sterling Japanese Yen
Similar Organizations
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Namur Invest
Namur Invest investment in Post-IPO Debt - VolitionRx
Official Site Inspections
http://www.volition.com Semrush global rank: 1.66 M Semrush visits lastest month: 14.8 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VolitionRx" on Search Engine
VolitionRx Ltd (VNRX)
Mar 19, 2024 Company Overview. Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and …See details»
Company Information :: VolitionRx Ltd (VNRX)
Company Profile. Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.See details»
VolitionRx - Crunchbase Company Profile & Funding
Legal Name VolitionRx Ltd. Stock Symbol NYSEMKT:VNRX. Company Type For Profit. Contact Email [email protected]. Phone Number 202-618-1750. Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.See details»
VolitionRx Limited Announces Full Fiscal Year 2021 Financial …
AUSTIN, Texas, March 30, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the full fiscal year ended December 31, 2021.See details»
Press Releases :: VolitionRx Ltd (VNRX)
Feb 2, 2024 VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update Nov 08, 2023 8:00am EST VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business UpdateSee details»
VolitionRX Company Profile - Craft
Mar 15, 2024 VolitionRx is a life sciences company which focuses on developing blood-based tests to diagnose a range of cancers. The Company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.See details»
VolitionRx Limited Announces Closing of $16.5 Million …
HENDERSON, Nev. , June 5, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, …See details»
VolitionRx Limited Announces Full Fiscal Year 2023 Financial …
HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business...See details»
VolitionRx Provides a Business Update and Appoints Key …
AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief Financial Officer,...See details»
VolitionRx Limited Announces Proposed Underwritten Public …
PR Newswire. May 31, 2023 · 5 min read. HENDERSON, Nev., May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company,...See details»
VolitionRx Limited Announces Full Fiscal Year 2022 Financial …
HENDERSON, Nev., March 15, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2022.See details»
VolitionRx Limited Announces Pricing of $16.5 Million …
Jun 1, 2023 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares...See details»
VolitionRx Limited Announces Full Fiscal Year 2022 Financial …
HENDERSON, Nev., March 15, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business...See details»
VolitionRx Limited Announces Closing of $8.7 Million …
HENDERSON, Nevada , Feb. 22, 2023 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 4,945,000 shares of its common stock, including the exercise in full of the underwriter’s overallotment option, at …See details»
VolitionRx - Funding, Financials, Valuation & Investors - Crunchbase
VolitionRx has raised a total of. $66.3M. in funding over 12 rounds. Their latest funding was raised on Mar 26, 2024 from a Post-IPO Equity round. VolitionRx is registered under the ticker NYSEMKT:VNRX . VolitionRx is funded by 2 investors. WE International and WE International are the most recent investors. Unlock for free.See details»
VolitionRx Limited Announces Third Quarter 2023 Financial …
HENDERSON, Nev. , Nov. 14, 2023 /PRNewswire/ — VolitionRx Limited (NYSE American: VNRX) (“Volition”) today announced financial results and a business update for the third quarter ended September 30, 2023. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results.See details»
VolitionRx Secures Approximately $5.5 Million in Belgium …
Dec 5, 2023 Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for …See details»
BlackBerry Customer Success – VolitionRx
With operations teams in Belgium, London, Singapore, and the United States, VolitionRx is a global organization. Each group uses its own equipment and is subject to its regulatory environment.See details»
VolitionRx Limited Announces Closing of $16.5 Million …
HENDERSON, Nev., June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced...See details»
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com
2 days ago VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.10. VolitionRx ( NYSE:VNRX - Get Free Report) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.11) earnings per share for the quarter. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of …See details»